Novartis drug pelacarsen showed no effect on heart attack and stroke rates despite lowering lp(a) levels. This was highlighted in a study presented at the American Heart Association’s annual meeting. Similarly, a study from Novo Nordisk evaluating an anti-inflammatory targeting IL-6 also demonstrated no benefit.
These findings raise questions about the reliability of new technologies in drug development. Both companies may need to reassess their strategies in addressing cardiovascular risks.
Source: statnews.com · Image: 2015 Heart Ball (17300654251) by Army Medicine, CC BY 2.0, via Wikimedia Commons
Planning your supply chain?
The API & FDF Intelligence database shows where manufacturers are located, which certificates they hold, and which markets are overheated.
With direct contacts for every supplier and holder, you can move from weeks of outreach to decisions made in hours.
Use the database as your supply chain compass →
Use the database as your supply chain compass →
